A nano-sized PARACEST-fluorescence imaging contrast agent facilitates and validates in vivo CEST MRI detection of glioma
- Meser M. Ali(corresponding author),
- Mohammed P.I. Bhuiyan,
- Branislava Janic,
- Nadimpalli R.S. Varma,
- Tom Mikkelsen,
- James R. Ewing
- Henry Ford Health System,
- University of Arizona
Abstract
Aim: The authors have investigated the usefulness of in vivo chemical exchange saturation transfer MRI for detecting gliomas using a dual-modality imaging contrast agent. Materials & methods: A paramagnetic chemical exchange saturation transfer MRI contrast agent, Eu-1,4,7,10- tetraazacclododecane-1,4,7,10-tetraacetic acid-Gly4 and a fluorescent agent, DyLight® 680, were conjugated to a generation 5 polyamidoamine dendrimer to create the dual-modality, nano-sized imaging contrast agent. Results: The agent was detected with in vivo chemical exchange saturation transfer MRI in an U87 glioma model. These results were validated using in vivo and ex vivo fluorescence imaging. Conclusion: This study demonstrated the merits of using a nano-sized imaging contrast agent for detecting gliomas and using a dual-modality agent for detecting gliomas at different spatial scales. Original submitted 9 January 2012; Revised submitted 18 April 2012; Published online 14 August 201.
Publication Information
Output type
Original language
English (US)Pages from-to (Number of pages)
Pages 1827-1837 (11 pages)Journal (Volume, Issue Number)
Nanomedicine (Volume 7, Issue 12)Publication milestones
- Published - 12/2012
Publication status
ISSN
1743-5889Publication IDs
- Scopus: 84871324512
- PubMed: 22891866
